...as senior health care equity research analysts. For the last five years, Rauch was at Everen/First...

...Dan Durkin will pick up his sellside duties, along with new hire Jeffrey Kraws from Everen...

...Amgen Inc. (AMGN), Thousand Oaks, Calif. Business: Biopharmaceuticals Everen Securities analyst Albert Rauch lowered his long-term...

...Biogen Inc. (BGEN), Cambridge, Mass. Business: Biopharmaceuticals Everen Securities analyst Albert Rauch lowered his intermediate-term rating...

...Incyte Pharmaceuticals Inc. (INCY), Palo Alto, Calif. Business: Drug discovery Everen Securities analyst Albert Rauch began...

...Affymetrix Inc. (AFFX), Santa Clara, Calif. Business: Enabling technology Everen Securities analyst Albert Rauch increased his...

...Vertex Pharmaceuticals Inc. (VRTX), Cambridge, Mass. Business: Cancer, Infectious diseases Everen Securities analyst Albert Rauch raised...

...2000 estimate to $4 from $3.86. His new price target is $136, up from $125. Everen...

...Biogen Inc. (BGEN), Cambridge, Mass. Business: Biopharmaceuticals Everen Securities analyst Albert Rauch began coverage with an...

...EPS estimate to $3.18 from $3.14 to reflect better than expected third quarter earnings (B13). Everen...